


1st Quarter 2023 Report (January - March)

Percent change evaluated relative to 1st Quarter 2022

Summary

- The percentage of prescribers enrolled in the PDMP system has stayed consistent compared to the 1st quarter of 2022 (*Figure 1 and Table 1*).
- Total Gateway automated queries and reports viewed have decreased, while web queries have increased from the 1st quarter of 2022 (*Figure 2 and Table A-1*).
- Overall, the total number of prescriptions for controlled substances have increased (2.2%) since the 1st quarter of 2022. Gabapentin is the most prescribed substance in the system with a slight increase (+2.2%) in prescriptions over Q1 2022. Stimulant prescriptions continue to increase with amphetamine prescriptions up 2.7% and methylphenidate prescriptions increasing 15.4% (*Table 4*).




- *Figure 1* shows the percentage of PDMP-enrolled prescribers over time from 2013-2022. Registration has remained high since 2018, especially among top prescribers.

Table 1. PDMP Enrollment and System Use for Oregon Prescribers¹: January - March 2023.

User Type	Prescribers	Enrolled	Web Query	Automated Query	Total Query
All Prescribers (by DEA)	19,108	16,350 / 85.6%	3,825 / 23.4%	12,546 / 76.7%	13,309 / 81.4%
Top 4,000 Prescribers	4,000	3,905 / 97.6%	1,707 / 43.7%	3,521 / 90.2%	3,694 / 94.6%
Top 2,000 Prescribers	2,000	1,972 / 98.6%	974 / 49.4%	1,807 / 91.6%	1,892 / 95.9%

¹Counts provided by unique DEA number, but providers may have multiple DEA numbers.

- Controlled substances were prescribed by 19,108 Oregon providers in Q1 of 2023.
- During the 1st quarter, 81.4% of enrolled prescribers, 94.6% of the top 4,000 prescribers, and 95.9% of the top 2,000 prescribers used the web portal or integration.
- The percentage of enrolled prescribers querying the PDMP has slightly decreased since the 1st quarter of 2022, when 83.9% of enrolled prescribers submitted queries.




- Total web portal queries have increased from the same quarter last year, with the largest increase seen in queries by pharmacies. Healthcare providers usage of the web portal slightly decreased (-1.6%) compared to the 1st quarter of 2022.

- The total number of Gateway electronic health record (EHR)-integrated automated queries and reports viewed has decreased over the same quarter last year.
- *Table A-1* in the appendix includes the summary statistics for this data.

Table 2. Special Requests: January - March 2023.

Measure	Count
Patient Records	8
Healthcare Boards	33
Law Enforcement	14
Total Special Requests	55

- 55 special requests were received and processed by PDMP staff.
- Healthcare boards continue to be the most frequent originators of these requests.



- *Figure 3* and *Table 3* represents usage for providers who are registered with the PDMP.
- In general, account numbers have stayed consistent among disciplines with an 9.6% increase in enrollment for MD/PA/DO disciplines over Q1 2022.
- NP/CNS-PP disciplines increased usage of the web portal 10.2% over Q1 2022.

Table 3. Query by Clinical User Group for Enrolled Providers: January – March 2023.

Discipline	Total Accounts (by DEA) ¹	% Change ²	Web User ³	% Change ²	Integrated User ³	% Change ²
MD/PA/DO	19,541	9.6%	1,702	1.4%	15,084	10.0%
NP/CNS-PP	4,666	4.1%	1,096	10.2%	3,508	6.6%
RPh	3,183	-1.9%	1,322	-4.9%	419	-1.0%
Delegates	3,158	-2.8%	1,698	0.1%	NA	NA
DDS/DMD	2,675	-1.6%	388	-3.6%	268	14.6%
ND	544	-4.7%	180	22.0%	446	-0.9%

¹Counts provided by unique DEA Number, but providers may be associated with multiple DEA numbers.

²Percent change evaluated relative to same quarter during the prior year.

³Query data drawn from Appriss AWAxE web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query.

- Integrated Gateway usage continues to be popular among all clinical user groups, especially MD/PA/DO disciplines, which increased queries 10.0% over Q1 2022.

Table 4. Top Prescriptions: January – March 2023.

Drug	Number of Rx	% of all Rx	% Change
All	1,642,249	100%	2.2%
Gabapentin	232,631	14.2%	2.2%
Oxycodone	223,103	13.6%	3.5%
Hydrocodone	213,248	13%	-3.7%
Amphetamine	197,145	12%	2.7%
Methylphenidate	94,027	5.7%	15.4%
Lorazepam	81,962	5%	0.8%
Tramadol	74,558	4.5%	-2.1%
Zolpidem	60,657	3.7%	-3.9%
Alprazolam	57,457	3.5%	-2.8%
Clonazepam	55,461	3.4%	-3.4%

- Overall, the number of prescriptions increased 2.2% relative to the 1st quarter of 2022.
- Gabapentin is the top prescribed drug in the PDMP (14.2% of all prescriptions) with a 2.2% increase in prescribing relative to Q1 2022. The addition of gabapentin as a PDMP covered substance was effective as of January 1st, 2020.
- Prescriptions for the stimulants amphetamine and methylphenidate increased by 2.7% and 15.4% relative to the same quarter last year.

Table 5. Prescriptions for Buprenorphine and Naloxone: January – March 2023.

Drug	Number of Rx	% of all Rx	% Change
Buprenorphine/Naloxone	42,556	2.6%	-1.1%
Buprenorphine	24,721	1.5%	8.9%
Naloxone	10,489	0.6%	74.8%

- Prescriptions for buprenorphine and naloxone increased while buprenorphine/naloxone combinations slightly decreased relative to the same quarter last year.
- Naloxone prescriptions will not be collected by the PDMP starting Fall 2023.

APPENDIX

Table A-1. PDMP Queries Summary Statistics: January – March 2022.

User Type	Web Portal		Gateway Integration			
	Queries ¹	% Change ²	Automated Queries ¹	% Change ²	Reports Viewed ¹	% Change ²
Healthcare providers	87,179	-1.6%	5,399,598	-10.3%	744,207	-27.4%
Pharmacies	100,988	43.1%	1,203,044	3.8%	637,613	9.3%
Delegates	156,452	0.1%	NA	NA	NA	NA
Queries²	344,747	9.3%	6,602,642	-8%	1,381,820	-14.1%

¹Query data drawn from AWA RxE web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and query date.

²Percent change evaluated relative to same quarter the prior year.